Integra Lifesciences Holdings Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Integra Lifesciences Holdings Corp 公司

Integra LifeSciences Holdings Corporation 是一家全球医疗技术公司。该公司通过两个部门制造和销售医疗技术和产品：Codman Specialty Surgical (CSS) 和 Tissue Technologies (TT)。CSS 部门包括用于一系列专业的技术和仪器，例如神经外科、神经重症监护和耳鼻喉科。CSS 业务包括一系列品牌，例如 Codman、DuraGen、DuraSeal、CUSA、Mayfield、Bactiseal 和 Certas Plus，用于管理多种疾病状态，包括脑肿瘤、创伤性脑损伤、脑积水和其他神经系统疾病。该公司提供用于精密、专业和一般外科手术的仪器。TT 部门专注于三个主要领域：复杂伤口手术、外科重建和外周神经修复。TT 部门提供皮肤和伤口修复、骨移植以及神经和肌腱修复产品。

公司简介

公司代码IART

公司名称Integra Lifesciences Holdings Corp

上市日期Aug 16, 1995

CEOMs. Mojdeh Poul

员工数量4396

证券类型Ordinary Share

年结日Aug 16

公司地址1100 Campus Road

城市PRINCETON

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编08540

电话16092750500

网址https://www.integralife.com/

公司代码IART

上市日期Aug 16, 1995

CEOMs. Mojdeh Poul

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Stuart M. Essig, Ph.D.

Executive Chairman of the Board

1.59M

-11.20%

Mr. Christian S. (Chris) Schade

Independent Director

90.03K

+41.78%

Dr. Keith Bradley, Ph.D.

Independent Director

89.14K

+27.45%

Mr. Michael J. Mcbreen

Executive Vice President, President - Codman Specialty Surgical

70.34K

+25.21%

Ms. Lea Daniels Knight

Chief Financial Officer, Executive Vice President

58.58K

-4.19%

Mr. Jeffrey Mosebrook

Senior Vice President - Finance, Principal Accounting Officer

35.79K

-10.69%

Mr. Harvinder Singh

Executive Vice President, President - International Business

13.25K

+1024.00%

Ms. Mojdeh Poul

President, Chief Executive Officer, Director

--

Ms. Shaundra D. Clay

Independent Director

--

Mr. Chris Ward

IR Contact Officer

--

名称

名称/职务

职务

持股

持股变动

Dr. Stuart M. Essig, Ph.D.

Executive Chairman of the Board

1.59M

-11.20%

Mr. Christian S. (Chris) Schade

Independent Director

90.03K

+41.78%

Dr. Keith Bradley, Ph.D.

Independent Director

89.14K

+27.45%

Mr. Michael J. Mcbreen

Executive Vice President, President - Codman Specialty Surgical

70.34K

+25.21%

Ms. Lea Daniels Knight

Chief Financial Officer, Executive Vice President

58.58K

-4.19%

Mr. Jeffrey Mosebrook

Senior Vice President - Finance, Principal Accounting Officer

35.79K

-10.69%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Neurosurgery

190.91M

49.89%

Wound Reconstruction and Care

74.78M

19.54%

Instruments

50.95M

13.31%

ENT

38.80M

10.14%

Private Label

27.21M

7.11%

地区USD

名称

营收

占比

United States

282.22M

73.75%

Asia Pacific

45.10M

11.79%

Europe

35.33M

9.23%

Rest of World

20.00M

5.23%

业务

地区

业务USD

名称

营收

占比

Neurosurgery

190.91M

49.89%

Wound Reconstruction and Care

74.78M

19.54%

Instruments

50.95M

13.31%

ENT

38.80M

10.14%

Private Label

27.21M

7.11%

股东统计

更新时间: 8月15日周五

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.11%

TRU ST Partnership, L.P.

10.93%

The Vanguard Group, Inc.

9.63%

Rubric Capital Management LP

9.44%

Fuller & Thaler Asset Management Inc.

5.00%

其他

52.90%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.11%

TRU ST Partnership, L.P.

10.93%

The Vanguard Group, Inc.

9.63%

Rubric Capital Management LP

9.44%

Fuller & Thaler Asset Management Inc.

5.00%

其他

52.90%

股东类型

持股股东

占比

Investment Advisor

37.14%

Investment Advisor/Hedge Fund

35.40%

Hedge Fund

18.02%

Corporation

10.93%

Research Firm

3.23%

Individual Investor

3.18%

Pension Fund

1.43%

Bank and Trust

0.44%

Sovereign Wealth Fund

0.04%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

600

89.38M

114.72%

-18.72M

2025Q1

635

87.01M

111.97%

-18.30M

2024Q4

636

81.93M

106.10%

-20.27M

2024Q3

638

82.93M

106.93%

-12.58M

2024Q2

628

84.82M

107.92%

-1.75M

2024Q1

613

79.36M

101.18%

-3.69M

2023Q4

597

79.81M

101.26%

-5.74M

2023Q3

592

81.88M

100.31%

-3.94M

2023Q2

587

82.30M

100.29%

-6.57M

2023Q1

579

85.87M

104.63%

-5.43M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

9.75M

12.55%

-341.75K

-3.38%

Mar 31, 2025

TRU ST Partnership, L.P.

8.52M

10.96%

--

Feb 28, 2025

The Vanguard Group, Inc.

7.47M

9.61%

-66.65K

-0.88%

Mar 31, 2025

Rubric Capital Management LP

4.64M

5.98%

+2.03M

+77.35%

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

3.92M

5.05%

-9.76K

-0.25%

Mar 31, 2025

Invesco Advisers, Inc.

3.13M

4.02%

+1.36M

+77.42%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.58M

3.32%

+212.16K

+8.95%

Mar 31, 2025

State Street Global Advisors (US)

2.75M

3.54%

-105.48K

-3.70%

Mar 31, 2025

Boston Management and Research

2.74M

3.53%

--

Mar 31, 2025

Paradigm Capital Management, Inc.

1.39M

1.78%

-45.90K

-3.21%

Mar 31, 2025

持股ETF

更新时间: 9月2日周二

机构名称

占比

iShares Neuroscience and Healthcare ETF

2.12%

SPDR S&P Health Care Equipment ETF

1.78%

ROBO Global Healthcare Technology & Innovation ETF

1.12%

Invesco S&P SmallCap Health Care ETF

0.59%

Invesco NASDAQ Future Gen 200 ETF

0.47%

First Trust Small Cap Value AlphaDEX Fund

0.41%

VictoryShares US Small Mid Cap Value Momentum ETF

0.23%

Inspire Small/Mid Cap ESG ETF

0.21%

First Trust Small Cap Core Alphadex Fund

0.2%

Royce Quant Small-Cap Quality Value ETF

0.17%

iShares Neuroscience and Healthcare ETF

占比2.12%

SPDR S&P Health Care Equipment ETF

占比1.78%

ROBO Global Healthcare Technology & Innovation ETF

占比1.12%

Invesco S&P SmallCap Health Care ETF

占比0.59%

Invesco NASDAQ Future Gen 200 ETF

占比0.47%

First Trust Small Cap Value AlphaDEX Fund

占比0.41%

VictoryShares US Small Mid Cap Value Momentum ETF

占比0.23%

Inspire Small/Mid Cap ESG ETF

占比0.21%

First Trust Small Cap Core Alphadex Fund

占比0.2%

Royce Quant Small-Cap Quality Value ETF

占比0.17%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Integra Lifesciences Holdings Corp

15.380USD

Integra Lifesciences Holdings Corp

15.380

概览

公司

财务

分析